0001237899-20-000008.txt : 20200214 0001237899-20-000008.hdr.sgml : 20200214 20200214160917 ACCESSION NUMBER: 0001237899-20-000008 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200212 FILED AS OF DATE: 20200214 DATE AS OF CHANGE: 20200214 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: STAHL NEIL CENTRAL INDEX KEY: 0001226689 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-19034 FILM NUMBER: 20619697 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: REGENERON PHARMACEUTICALS, INC. CENTRAL INDEX KEY: 0000872589 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 133444607 STATE OF INCORPORATION: NY FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 777 OLD SAW MILL RIVER ROAD CITY: TARRYTOWN STATE: NY ZIP: 10591 BUSINESS PHONE: 9148477000 MAIL ADDRESS: STREET 1: 777 OLD SAW MILL RIVER ROAD CITY: TARRYTOWN STATE: NY ZIP: 10591 FORMER COMPANY: FORMER CONFORMED NAME: REGENERON PHARMACEUTICALS INC DATE OF NAME CHANGE: 19930328 4 1 edgardoc.xml PRIMARY DOCUMENT X0306 4 2020-02-12 0 0000872589 REGENERON PHARMACEUTICALS, INC. REGN 0001226689 STAHL NEIL 777 OLD SAW MILL RIVER ROAD TARRYTOWN NY 10591 0 1 0 0 EVP Research and Development Common Stock 2020-02-12 4 M 0 25000 52.03 A 36380 D Common Stock 2020-02-12 4 F 0 14722 402.34 D 21658 D Common Stock 2020-02-13 4 S 0 4302 399.8 D 17356 D Common Stock 2020-02-13 4 S 0 2608 400.54 D 14748 D Common Stock 2020-02-13 4 S 0 2058 401.46 D 12690 D Common Stock 2020-02-13 4 S 0 1279 402.35 D 11411 D Common Stock 2020-02-13 4 S 0 31 406.44 D 11380 D Common Stock 5736 I By 401(k) Plan Common Stock 7831 I by 2018 GRAT Common Stock 13700 I by 2019 GRAT Non-Qualified Stock Option (right to buy) 52.03 2020-02-12 4 M 0 25000 0.0 D 2021-12-16 Common Stock 25000 63079 D Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Represents volume-weighted average price of sales of 4,302 shares of Company stock on February 13, 2020 at prices ranging from $399.04 to $399.98. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 13, 2020 at each separate price. Represents volume-weighted average price of sales of 2,608 shares of Company stock on February 13, 2020 at prices ranging from $400.01 to $400.93. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 13, 2020 at each separate price. Represents volume-weighted average price of sales of 2,058 shares of Company stock on February 13, 2020 at prices ranging from $401.11 to $401.97. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 13, 2020 at each separate price. Represents volume-weighted average price of sales of 1,279 shares of Company stock on February 13, 2020 at prices ranging from $402.04 to $402.97. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 13, 2020 at each separate price. With respect to 75,000 underlying shares (of which 50,000 remain outstanding), the option became exercisable on December 31, 2014, based upon the satisfaction by the company of certain performance criteria during the period ended December 31, 2014. With respect to 48,079 underlying shares (of which 13,079 remain outstanding), the stock option award vested in four equal annual installments, commencing one year after the date of grant. /s/**Neil Stahl 2020-02-14